Skip to content
CityAM
Main navigation
Sign Up
  • News
    • Latest News
    • Property
    • Media
    • Technology
    • Retail and leisure
    • Transport and infrastructure
    • Law & professional services
    • Legal Notices
    • Banking
    • Politics
    • CFA Institute Talk
  • Markets & Economics
    • Markets & Economics News
    • Economics
    • Markets
    • The Trend Micro Cybersecurity Knowledge Hub
    • Talk Crypto
    • M&A Talk
  • Crypto A.M.
    • Crypto News
    • Crypto Magazine
    • Crypto AM Summit & Awards 2022
  • Opinion
    • Features
    • Letters
    • The City View
  • Money
    • Jobs and Money News
    • Personal Development
    • Jobs
    • Fintech
    • Money
    • Personal Finance
    • Nine smart ideas for improving your financial outlook
    • Warwick Business School
  • Unwind
    • Life & Style
    • Sport
    • The Punter
    • The Magazine
    • Travel
    • Sport Business
    • The Punter Podcast
    • Culture
    • Six Nations 2023
    • LIV Golf
    • Aramco Team Series
  • Impact A.M.
    • Impact A.M.
    • DiverCity Podcast
    • Partner Hubs
  • Latest Paper
  • Jobs
  • CityAM Awards 2023
  • Charity

Vaccine

  • Moderna investors left disappointed by vaccine maker’s subdued sales forecast despite strong fourth quarter

    Moderna

    Moderna has reaffirmed annual sales forecast of $5bn (£4.1bn) for its Covid-19 vaccines despite its fourth-quarter sales exceeding estimates, on expectations of lower demand for the shots in the fourth year of the pandemic. Sales of the vaccine, Moderna’s sole commercial product, were expected to fall sharply this year from $18.4bn in 2022 as most people [...]

  • Astrazeneca’s shares rise, as cancer drug uptake offsets fall in sales of pharma giant’s Covid-19 vaccine

    Pharma results

    Astrazeneca has posted what it claimed were “strong” financial results for the full year 2022 as surging demand for cancer medicines offset a fall in Covid vaccine revenues. Shares in Astrazeneca jumped on the news as the firm said it expects another year of double-digit revenue growth in 2023. The British firm’s strong results came [...]

  • Pfizer and BioNTech countersue Moderna in Covid-19 patent row

    big pharma

    Pfizer and German partner BioNTech shot back at competitor Moderna last night in the latest jab in the Covid-19 vaccine patent lawsuit. The sparring over allegations from Moderna that Pfizer and BioNTech violated the rights its three patents it created prior to the pandemic has been ongoing since August. All three companies are also embroiled [...]

  • Protect your health this winter

    November 30, 2022  |  Sponsored

    As the nights draw in, it’s time to think about protecting our health this winter. We are preparing for a tough few months – with the potential for a further Covid-19 wave and a difficult flu season – and of course not everything can be prevented. But we can reduce the risk of Covid-19 and [...]

  • Novavax dials back revenue expectations despite Covid-19 jab success

    November 9, 2022

    Novavax, an American biotech firm, has dialled back its revenue expectations, despite roaring success from its Covid-19 vaccine. In a statement last night, the company announced that it now forecasts full year revenue to be on the low end of its previously forecast range of between $2bn (£1.7bn) and $2.3bn (£2bn). The company, which was [...]

  • Moderna rejects request from China for Covid-19 vaccine technology

    October 2, 2022

    Moderna has reportedly refused a request from China to reveal the technology behind its Covid-19 vaccine. The rejection prompted negotiations for its sale there to fall apart, the Financial Times reported, citing people familiar with the matter. The US pharmaceutical company remains “eager” to sell its product in China after negotiations between 2020 and 2021 [...]

  • Moderna to sue Pfizer over Covid vaccine tech

    August 26, 2022

    Moderna has said it will be suing Pfizer and its German partner BioNTech for patent infringement for the first Covid-19 vaccine.

  • NGOs including Oxfam and Save the Children call on Covid-19 Inquiry to probe global impact of UK vaccine buying

    August 22, 2022

    A string of NGOs, including Oxfam, have called on the chair of the Government’s Covid-19 Inquiry to probe the impacts of UK pandemic policy on the global stage.   In a letter to chair Baroness Hallett today, the NGOs said: “Given the inquiry’s focus on the impact of the pandemic on inequalities, this should include [...]

  • Government braces to fund ‘substantial’ number of Covid-19 vaccine liabilities

    July 13, 2022

    The government is bracing to fund a “substantial” number of liabilities relating to negative impacts from Covid-19 jabs, having spent more than £34bn on the vaccine rollout so far.   The Department of Health and Social Care told vaccine manufacturers at the start of the programme that it would cover future claims against producers for [...]

  • NHS agrees to pay £120k in damages to bereaved fiancee in covid first

    June 21, 2022

    A woman whose fiance died after taking the covid jab has claimed to have received the first covid vaccine damage payment of £120,000.

Posts navigation

  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 47
  • Next

Trending Articles

  • James May: Top Gear's future and my real relationship with Jeremy Clarkson

  • Pound on course for highest level against US dollar in over a year, City analysts bet

  • House prices: London and south east falling faster than rest of the country

  • Interview: Why Octopus Energy boss Greg Jackson is still powered up

Subscribe

Subscribe to the City A.M. newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Advertising
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • News
  • Markets & Economics
  • Opinion
  • Jobs and Money
  • Unwind
  • Crypto A.M.
  • The Punter
  • COP 26
  • Awards 2023

Follow us for breaking news and latest updates

  • Newsletters
  • Latest paper
  • Advertising
  • CryptoAM.io
  • Awards
  • About
  • Tickets
Copyright 2023 City A.M. Limited